Table 3.

Grade 3 or 4 or 5 AEs possibly, probably, or definitely related to treatments, according to arm

RT/temozolomideVandetanib/RT/temozolomide
(N = 29)(N = 69)
Hematologic
 Anemia02 (2.9%)
 Leukopenia2 (6.9%)8 (11.6%)
 Lymphopenia8 (27.6%)30 (43.5%)
 Neutropenia3 (10.3%)8 (11.6%)
 Thrombocytopenia5 (17.2%)5 (7.2%)
Dermatology/skin
 Pruritis/itching01 (1.4%)
 Rash–acneiform01 (1.4%)
 Rash–desquamation03 (4.3%)
 Rash–erythema multiforme02 (2.9%)
Gastrointestinal
 Colonic fistula01 (1.4%)
 Colonic perforation01 (1.4%)
 Diarrhea01 (1.4%)
Hepatobiliary/pancreas
 Cholecystitis01 (1.4%)
 Infection2 (6.9%)2 (2.9%)
Metabolic/laboratory
 ALT/SGPT elevation3 (10.3%)6 (8.7%)
 AST/SGOT elevation1 (3.4%)3 (4.3%)
 Hyperbilirubinemia02 (2.9%)
 Hyperglycemia01 (1.4%)
 Hyponatremia01 (1.4%)
 Hypophosphatemia03 (4.3%)
Nervous system disorders
 CNS cerebrovascular ischemia01 (1.4%)
 Dizziness01 (1.4%)
 Headache1 (3.4%)0
 Imbalance/weakness01 (1.4%)
Pulmonary/upper respiratory
 Dyspnea03 (4.3%)
 Hypoxia01 (1.4%)
Vascular disorders
 Hypertension01 (1.4%)
 Thrombosis/thrombus/embolism03 (4.3%)
 Fatigue1 (3.4%)4 (5.8%)